Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.

By L. Carmona, J. Gómez-Reino, V. Rodríguez-valverde, D. Montero, E. Pascual-Gómez, E. Mola, L. Carreño, M. Figueroa. Arthritis & Rheumatism, 2005

698 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features (2011, background): “Obtaining Mantoux purified protein derivative skin testing for tuberculosis was recommended prior to initiation of TNF inhibitors for all patients (level C) (111).”
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008, background): “…certain infections, particularly tuberculosis (TB) and other infections caused by intracellular microbes, after treatment with TNF antagonists (Askling et al., 2005; Carmona et al., 2005; Listing et al., 2005; Askling et al., 2006; Bongartz et al., 2006; Carmona et al., 2006; Schiff et al., 2006b).”
Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017, background): “to reduce the incidence of TB disease include household contacts of active TB patients [55, 63], native Alaskan communities [64], residents of mental health facilities [65], persons with HIV infection [66–69], and individuals treated with TNF inhibitors [70, 71].”